Breaks Categories: Stock Spotlights

TuesdayFeb 06, 2018 11:10 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Agreement to Create Cannabis-infused Edibles Utilizing DehydraTECH™ Delivery Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently entered an agreement with a cannabis-infused edibles manufacturer, Cannfections Group Inc. The agreement is expected to generate new cannabis-based edible products using Lexaria’s patented DehydraTECH™ delivery technology. An article discussing the agreement reads: “On January 25, 2018, Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) announced that it had entered into a seven-year agreement with Cannfections Group Inc. to provide its patented DehydraTECH™ technology for the development of a new range of cannabis-infused chocolates and gummies (http://cnw.fm/3oV1q). Cannfections is a new company, established by one of Canada’s leading chocolate manufacturers with over 85 years…

Continue Reading

MondayJan 29, 2018 11:38 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system…

Continue Reading

FridayJan 26, 2018 2:31 pm

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Aims to Multiply Production Capabilities in 2018

Premium cannabis lifestyle brand DOJA Cannabis Company (CSE: DOJA) (OTC: DJACF) is a licensed marijuana producer under Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The company recently expanded its production capacity through the acquisition of a new warehouse. A recent article discussing the company reads: “As a licensed cannabis producer under the ACMPR through its wholly-owned subsidiary Northern Lights Marijuana Company, DOJA currently operates a 7,100-square-foot production facility that is licensed by Health Canada. The company recently acquired second facility is a 22,580-square-foot warehouse where its FUTURE LAB will be housed. The FUTURE LAB will be a state-of-the-art…

Continue Reading

WednesdayJan 24, 2018 11:26 am

CannabisNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enhances Life by Uniting Nature and Science

An ongoing concern in North America, as reported by the Centers for Disease Control and Prevention, is that Americans are only taking advantage of preventive medical services about half as often as they should. Endeavoring to become a pioneer in preventative medicine, health science company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the belief that, in healthcare, prevention is the best policy, and that nature and science can unite to offer a range of innovative, untapped solutions to address unmet clinical needs. As quoted in a recent article: “PreveCeutical is taking a new look at…

Continue Reading

WednesdayJan 24, 2018 11:19 am

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH™ Platform Expands Portfolio

Food bioscience company Lexaria Bioscience’s (CSE: LXX) (OTCQB: LXRP) strategic focus for 2018 is on out-licensing its proprietary technology, DehydraTECH™. The company intends to out-license to third-party partners using a high margin royalty model. An article discussing the company’s drug delivery platform reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a research-driven company that has developed and out-licenses a patented drug delivery platform called DehydraTECH™ that changes the way active pharmaceutical ingredients (“APIs”) enter the body orally. According to a new report by Million Insights (http://cnw.fm/fGid9), the global API market is anticipated to reach $239.8 billion by 2025, with…

Continue Reading

FridayJan 19, 2018 12:24 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Eyes Bright Future Following 2017 Success

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) demonstrated several transformative developments in 2017. The company’s Intellectual Property (“IP”) was strengthened, it was awarded broad patents, and it secured finances during the year. Now, Lexaria is concentrating on making 2018 an even more fruitful year. An article discussing the company’s recent progress reads: “The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit…

Continue Reading

ThursdayJan 04, 2018 11:31 am

CannabisNewsBreaks – DOJA Cannabis Company Ltd. (CSE: DOJA) (OTC: DJACF) Northern Lights Subsidiary Making Strides Toward Sales License

Premium cannabis lifestyle brand DOJA Cannabis Company’s (CSE: DOJA) (OTC: DJACF) wholly owned subsidiary, Northern Lights Marijuana Company, is a Health Canada licensed cannabis producer on the track to gain a Sales License. An article discussing the company reads: “DOJA’s initial cannabis harvest, produced under the Access to Cannabis for Medical Purposes Regulations (ACMPR) license held by its subsidiary, Northern Lights Marijuana Company, will be inspected by Health Canada regulators as the last step before a Sales License can be awarded. Once DOJA passes this major milestone and receives its Sales License, the company can begin selling cannabis and position…

Continue Reading

WednesdayJan 03, 2018 11:49 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Highlights Hidden Value of Wide-ranging DehydraTECH™ Patent

Based in Kelowna, British Columbia, Canada, food bioscience company Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is a technology disruptor for edible CBD. An article discussing this reads: “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka said in an audio interview with the Uptick Newswire Podcast (http://cnw.fm/Refc4) that the company was not only surprised by how quickly it received its patent for DehydraTECH™; it was also surprised by the broadness of the patent awarded for its utilization in other sectors, which it had expected in 2018 and 2019. The company believes that the new patent has locked up the…

Continue Reading

TuesdayDec 26, 2017 12:44 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Set to Exploit the Cannabis Industry Utilizing Proprietary Technology

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) is well positioned in the booming cannabis industry with its patent-protected technology, DehyraTECH™, which enables a more efficient delivery and absorption of cannabinoids. An article discussing this reads: “Lexaria research and development partnership with the Canadian government’s National Research Council underscores the significance of its unique technology. Results from the endeavor are expected to support accelerating B2B relationships – and not just in the booming cannabis and CBD/hemp oil industry. Much more can be done to enhance and enable delivery of active pharmaceutical ingredients in a wide variety of important health-related fields, offering Lexaria…

Continue Reading

FridayDec 22, 2017 12:18 pm

CannabisNewsBreaks – Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) to Leverage Unique Compound Synergies for Pain Moderation

Based on evidence that cannabinoids and opioids can work in synergy to moderate pain, Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) and its research arm, Cannevert Therapeutics Ltd., intend to boost actions of opioid analgesics with a specific strain of cannabis. A recent article highlights the company’s approach in developing quality strains, stating, “Veritas Pharma employs a scientific approach to support medical cannabis claims and is intent on developing and commercializing the most effective strains of cannabis for medical use. The company is concerned that, with the rapid growth of the medical cannabis industry, product quality is inconsistent and…

Continue Reading